iPLA2β deficiency attenuates obesity and hepatic steatosis in ob/ob mice through hepatic fatty-acyl phospholipid remodeling

PLA2G6 or GVIA calcium-independent PLA2 (iPLA2β) is identified as one of the NAFLD modifier genes in humans, and thought to be a target for NAFLD therapy. iPLA2β is known to play a house-keeping role in phospholipid metabolism and remodeling. However, its role in NAFLD pathogenesis has not been supp...

Full description

Saved in:
Bibliographic Details
Main Authors: Deng, Xiuling (Author) , Wang, Jiliang (Author) , Jiao, Li (Author) , Utaipan, Tanyarath (Author) , Tuma-Kellner, Sabine (Author) , Stremmel, Wolfgang (Author) , Chamulitrat, Walee (Author)
Format: Article (Journal)
Language:English
Published: 9 February 2016
In: Biochimica et biophysica acta. Molecular and cell biology of lipids
Year: 2016, Volume: 1861, Issue: 5, Pages: 449-461
ISSN:1879-2618
DOI:10.1016/j.bbalip.2016.02.004
Online Access:Verlag, Volltext: https://doi.org/10.1016/j.bbalip.2016.02.004
Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S1388198116300257
Get full text
Author Notes:Xiuling Deng, Jiliang Wang, Li Jiao, Tanyarath Utaipan, Sabine Tuma-Kellner, Gerd Schmitz, Gerhard Liebisch, Wolfgang Stremmel, Walee Chamulitrat
Description
Summary:PLA2G6 or GVIA calcium-independent PLA2 (iPLA2β) is identified as one of the NAFLD modifier genes in humans, and thought to be a target for NAFLD therapy. iPLA2β is known to play a house-keeping role in phospholipid metabolism and remodeling. However, its role in NAFLD pathogenesis has not been supported by results obtained from high-fat feeding of iPLA2β-null (PKO) mice. Unlike livers of human NAFLD and genetically obese rodents, fatty liver induced by high-fat diet is not associated with depletion of hepatic phospholipids. We therefore tested whether iPLA2β could regulate obesity and hepatic steatosis in leptin-deficient mice by cross-breeding PKO with ob/ob mice to generate ob/ob-PKO mice. Here we observed an improvement in ob/ob-PKO mice with significant reduction in serum enzymes, lipids, glucose, insulin as well as improved glucose tolerance, and reduction in islet hyperplasia. The improvement in hepatic steatosis measured by liver triglycerides, fatty acids and cholesterol esters was associated with decreased expression of PPARγ and de novo lipogenesis genes, and the reversal of β-oxidation gene expression. Notably, ob/ob livers contained depleted levels of lysophospholipids and phospholipids, and iPLA2β deficiency in ob/ob-PKO livers lowers the former, but replenished the latter particularly phosphatidylethanolamine (PE) and phosphatidylcholine (PC) that contained arachidonic (AA) and docosahexaenoic (DHA) acids. Compared with WT livers, PKO livers also contained increased PE and PC containing AA and DHA. Thus, iPLA2β deficiency protected against obesity and ob/ob fatty liver which was associated with hepatic fatty-acyl phospholipid remodeling. Our results support the deleterious role of iPLA2β in severe obesity associated NAFLD.
Item Description:Gesehen am 29.10.2019
Im Titel ist "ob/ob" kursiv geschrieben
Physical Description:Online Resource
ISSN:1879-2618
DOI:10.1016/j.bbalip.2016.02.004